Low molecular weight heparin is a general term for a class of relatively low molecular weight heparin prepared by depolymerization of common heparin. It was developed in the 1970s by combining a new class of anticoagulant drugs. Compared with heparin therapy,LMWH has the advantages of high bioavailability in China, strong antithrombotic effect and less adverse behavior reaction in patients with bleeding. Therefore,LMWH has been widely applied in clinical studies.
Heparins Manufacturer: indication
Prevention of thromboembolic diseases (such as myocardial infarction, thrombophlebitis)
Treatment of thromboembolic diseases (venous thromboembolism of the lower extremities, DIC).
Prevention of blood clots during hemodialysis
Treatment included unstable and qualitative angina pectoris and non - Q - wave myocardial infarction
Heparins Manufacturer: Contraindication
Organ damage and risk of bleeding (peptic ulcer, hemorrhagic stroke, etc.)
Hypersensitivity to heparin, low molecular weight heparin and its derivatives.
Patients with a history of thrombocytopenia associated with low molecular weight heparin
Postpartum hemorrhage and severe liver and kidney dysfunction
Patients with severe hypertension, severe brain injury, and acute infective endocarditis.